EntreMed’s ENMD-2076 Demonstrates Tumor Regression In Human Colon Cancer Model

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076. The data were presented by John Tentler, Ph.D.

More: continued here

Filed under: Clinical Trials on October 26th, 2008